Home ETF List About

Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
IssuerBlackrock
ETF TickerBTEE(USD) LSE
ETF TickerBTEE.L(GBP) LSE

Holdings detail for ANIP

Stock NameANI Pharmaceuticals Inc
TickerANIP(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS00182C1036
LEI5493000T6CXTND40YH31

Show aggregate ANIP holdings

News associated with ANIP

HC Wainwright Forecasts Strong Price Appreciation for ANI Pharmaceuticals (NASDAQ:ANIP) Stock
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its target price increased by HC Wainwright from $93.00 to $121.00 in a report issued on Wednesday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 24.13% from the stock’s […] - 2025-09-19 03:05:01
ANI Pharmaceuticals (NASDAQ:ANIP) Reaches New 12-Month High Following Analyst Upgrade
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) hit a new 52-week high on Tuesday after Guggenheim raised their price target on the stock from $86.00 to $114.00. Guggenheim currently has a buy rating on the stock. ANI Pharmaceuticals traded as high as $96.66 and last traded at $96.30, with a volume of 66131 shares […] - 2025-09-10 02:20:55
ANI Pharmaceuticals (NASDAQ:ANIP) COO Sells $4,618,078.50 in Stock
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) COO Muthusamy Shanmugam sold 52,990 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $87.15, for a total transaction of $4,618,078.50. Following the completion of the sale, the chief operating officer directly owned 531,920 shares […] - 2025-08-21 05:19:08
Deutsche Bank AG Trims Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Deutsche Bank AG trimmed its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 6.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 218,086 shares of the specialty pharmaceutical company’s stock after selling 14,242 shares during […] - 2025-08-15 05:15:08
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Expected to Rise, Truist Financial Analyst Says
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its target price raised by investment analysts at Truist Financial from $65.00 to $77.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the specialty pharmaceutical company’s stock. Truist Financial’s target price suggests a potential downside of 12.84% […] - 2025-08-13 02:46:43
Victory Capital Management Inc. Has $1.13 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Victory Capital Management Inc. grew its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 22.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 16,863 shares of the specialty pharmaceutical company’s stock after buying an additional 3,086 shares during the period. Victory Capital […] - 2025-07-31 05:28:47
Bank of New York Mellon Corp Reduces Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Bank of New York Mellon Corp lessened its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 3.7% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 119,262 shares of the specialty pharmaceutical company’s stock after selling 4,570 shares during the quarter. Bank of New York Mellon Corp’s holdings in ANI Pharmaceuticals […] - 2025-07-23 04:30:44
Louisiana State Employees Retirement System Has $522,000 Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Louisiana State Employees Retirement System cut its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 2.5% during the first quarter, Holdings Channel.com reports. The firm owned 7,800 shares of the specialty pharmaceutical company’s stock after selling 200 shares during the quarter. Louisiana State Employees Retirement System’s holdings in ANI Pharmaceuticals were worth $522,000 […] - 2025-07-21 05:16:50
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $78.88 Consensus Target Price from Analysts
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the […] - 2025-07-18 02:23:01
GAMMA Investing LLC Has $95,000 Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
GAMMA Investing LLC lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 163.8% during the first quarter, Holdings Channel.com reports. The firm owned 1,419 shares of the specialty pharmaceutical company’s stock after purchasing an additional 881 shares during the period. GAMMA Investing LLC’s holdings in ANI Pharmaceuticals were worth $95,000 […] - 2025-07-07 04:17:14
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.13 Average PT from Brokerages
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received an average recommendation of “Buy” from the nine brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The […] - 2025-06-23 02:14:07
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.13 Average Target Price from Analysts
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received a consensus recommendation of “Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-05-29 02:27:28
Surprising Analyst 12-Month Target For VIOO
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-13 08:45:24
Comerica Bank Has $1.04 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Comerica Bank lowered its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 30.1% in the 4th quarter, HoldingsChannel reports. The firm owned 18,830 shares of the specialty pharmaceutical company’s stock after selling 8,099 shares during the period. Comerica Bank’s holdings in ANI Pharmaceuticals were worth $1,041,000 at the end of the […] - 2025-05-13 05:42:52
MetLife Investment Management LLC Has $630,000 Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
MetLife Investment Management LLC increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 6.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,397 shares of the specialty pharmaceutical company’s stock after buying an additional 675 […] - 2025-05-05 06:01:03
Dimensional Fund Advisors LP Raises Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Dimensional Fund Advisors LP raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 4.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 685,730 shares of the specialty pharmaceutical company’s stock after purchasing an additional 30,420 […] - 2025-05-05 05:20:53
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Analysts
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has been given an average rating of “Buy” by the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to […] - 2025-05-01 02:12:50
Legal & General Group Plc Acquires 2,585 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Legal & General Group Plc increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 5.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 48,425 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,585 shares during the quarter. Legal & General Group Plc’s holdings in ANI […] - 2025-04-24 05:18:54
Invesco Ltd. Lowers Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Invesco Ltd. lowered its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 10.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 197,545 shares of the specialty pharmaceutical company’s stock after selling 22,814 shares during the quarter. Invesco […] - 2025-04-23 05:08:58
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Expected to Rise, Truist Financial Analyst Says
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its target price upped by analysts at Truist Financial from $62.00 to $65.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the specialty pharmaceutical company’s stock. Truist Financial’s price target points to a potential downside of 5.73% from the company’s […] - 2025-04-23 02:42:48
Vanguard Group Inc. Sells 33,739 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Vanguard Group Inc. reduced its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 2.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,314,372 shares of the specialty pharmaceutical company’s stock after selling 33,739 shares during the quarter. Vanguard […] - 2025-04-11 04:52:47
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by StockNews.com
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday. Other equities analysts have also recently issued reports about the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on […] - 2025-04-10 03:13:02
Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) PT at $79.75
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The […] - 2025-04-09 02:04:49
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Position Trimmed by Corebridge Financial Inc.
Corebridge Financial Inc. reduced its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 7.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,778 shares of the specialty pharmaceutical company’s stock after selling 762 shares during the quarter. Corebridge […] - 2025-04-08 04:27:01
Thrivent Financial for Lutherans Reduces Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Thrivent Financial for Lutherans trimmed its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 1.5% in the 4th quarter, HoldingsChannel reports. The firm owned 12,828 shares of the specialty pharmaceutical company’s stock after selling 200 shares during the quarter. Thrivent Financial for Lutherans’ holdings in ANI Pharmaceuticals were worth $709,000 as of its […] - 2025-04-03 04:16:46
ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at Jefferies Financial Group
Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) in a report released on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $80.00 target price on the specialty pharmaceutical company’s stock. Several other analysts have also recently commented on ANIP. StockNews.com cut shares of ANI […] - 2025-03-17 04:26:54
JPMorgan Chase & Co. Begins Coverage on ANI Pharmaceuticals (NASDAQ:ANIP)
JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $85.00 price target on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a […] - 2025-03-14 04:34:45
Illinois Municipal Retirement Fund Decreases Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Illinois Municipal Retirement Fund lowered its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 8.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,533 shares of the specialty pharmaceutical company’s stock after selling 799 shares during the quarter. Illinois Municipal Retirement Fund’s […] - 2025-03-05 08:46:59
ANI Pharmaceuticals (NASDAQ:ANIP) Cut to Sell at StockNews.com
StockNews.com downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) from a hold rating to a sell rating in a report released on Monday morning. ANIP has been the subject of several other research reports. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an […] - 2025-03-04 04:50:49
Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $77.71
Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) have been given an average rating of “Buy” by the eight research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy […] - 2025-02-18 04:13:03

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) ANIP holdings

DateNumber of ANIP Shares HeldBase Market Value of ANIP SharesLocal Market Value of ANIP SharesChange in ANIP Shares HeldChange in ANIP Base ValueCurrent Price per ANIP Share HeldPrevious Price per ANIP Share Held
2025-11-11 (Tuesday)13,929USD 1,233,274ANIP holding decreased by -5432USD 1,233,2740USD -5,432 USD 88.54 USD 88.93
2025-11-10 (Monday)13,929ANIP holding increased by 36USD 1,238,706ANIP holding decreased by -17638USD 1,238,70636USD -17,638 USD 88.93 USD 90.43
2025-11-07 (Friday)13,893USD 1,256,344ANIP holding increased by 2779USD 1,256,3440USD 2,779 USD 90.43 USD 90.23
2025-11-06 (Thursday)13,893ANIP holding increased by 36USD 1,253,565ANIP holding decreased by -29870USD 1,253,56536USD -29,870 USD 90.23 USD 92.62
2025-11-05 (Wednesday)13,857USD 1,283,435ANIP holding decreased by -25774USD 1,283,4350USD -25,774 USD 92.62 USD 94.48
2025-11-04 (Tuesday)13,857ANIP holding increased by 36USD 1,309,209ANIP holding increased by 9206USD 1,309,20936USD 9,206 USD 94.48 USD 94.06
2025-11-03 (Monday)13,821USD 1,300,003ANIP holding increased by 47820USD 1,300,0030USD 47,820 USD 94.06 USD 90.6
2025-10-31 (Friday)13,821USD 1,252,183ANIP holding decreased by -18382USD 1,252,1830USD -18,382 USD 90.6 USD 91.93
2025-10-30 (Thursday)13,821ANIP holding increased by 180USD 1,270,565ANIP holding increased by 12456USD 1,270,565180USD 12,456 USD 91.93 USD 92.23
2025-10-29 (Wednesday)13,641ANIP holding increased by 72USD 1,258,109ANIP holding decreased by -7743USD 1,258,10972USD -7,743 USD 92.23 USD 93.29
2025-10-28 (Tuesday)13,569USD 1,265,852ANIP holding increased by 5835USD 1,265,8520USD 5,835 USD 93.29 USD 92.86
2025-10-27 (Monday)13,569USD 1,260,017ANIP holding decreased by -18726USD 1,260,0170USD -18,726 USD 92.86 USD 94.24
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ANIP by Blackrock for IE00BDZVHG35

Show aggregate share trades of ANIP

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY3690.87081.820 82.725USD 2,978 66.77
2025-11-06BUY3694.45690.040 90.482USD 3,257 66.52
2025-11-04BUY3695.12092.370 92.645USD 3,335 66.22
2025-10-30BUY18093.46091.665 91.845USD 16,532 65.79
2025-10-29BUY7292.23093.800 93.643USD 6,742 65.64
2025-10-22SELL-14493.76095.830 95.623USD -13,770 64.82 Loss of -4,435 on sale
2025-10-20BUY7295.12095.670 95.615USD 6,884 64.47
2025-10-17BUY18094.79095.940 95.825USD 17,249 64.29
2025-10-15BUY28890.10090.610 90.559USD 26,081 64.14
2025-10-03BUY25289.64092.520 92.232USD 23,242 63.84
2025-10-02BUY3689.13090.620 90.471USD 3,257 63.68
2025-09-30BUY7291.60093.210 93.049USD 6,700 63.35
2025-09-26BUY7293.05094.770 94.598USD 6,811 62.99
2025-09-25BUY7293.37095.120 94.945USD 6,836 62.80
2025-09-18BUY3897.48098.550 98.443USD 3,741 62.59
2025-09-17BUY11495.36098.450 98.141USD 11,188 62.38
2025-07-17SELL-7468.04068.390 68.355USD -5,058 62.07 Loss of -465 on sale
2025-07-11SELL-29664.96066.010 65.905USD -19,508 61.99 Loss of -1,159 on sale
2025-07-02BUY2,03565.22065.550 65.517USD 133,327 61.90
2025-06-25BUY7465.91066.860 66.765USD 4,941 61.79
2025-06-11BUY7462.78063.700 63.608USD 4,707 61.60
2025-06-10BUY7462.87064.450 64.292USD 4,758 61.59
2025-06-04SELL-3760.87062.100 61.977USD -2,293 61.60 Loss of -14 on sale
2025-04-23BUY3768.37070.300 70.107USD 2,594 60.77
2025-04-10SELL-29665.12066.000 65.912USD -19,510 59.99 Loss of -1,752 on sale
2025-04-08SELL-3763.05068.350 67.820USD -2,509 59.89 Loss of -293 on sale
2025-04-07SELL-3766.99068.820 68.637USD -2,540 59.81 Loss of -327 on sale
2025-04-04SELL-18567.52068.400 68.312USD -12,638 59.72 Loss of -1,590 on sale
2025-04-01BUY49068.02068.960 68.866USD 33,744 59.50
2025-03-31SELL-10866.95067.800 67.715USD -7,313 59.41 Loss of -897 on sale
2025-03-21BUY81564.26065.510 65.385USD 53,289 58.84
2025-03-14SELL-52862.49063.600 63.489USD -33,522 58.47 Loss of -2,649 on sale
2025-03-07SELL-6660.62062.760 62.546USD -4,128 58.27 Loss of -282 on sale
2025-03-04SELL-3359.13062.000 61.713USD -2,037 58.19 Loss of -116 on sale
2025-02-25BUY6654.51056.030 55.878USD 3,688 58.31
2025-02-19SELL-3359.99060.540 60.485USD -1,996 58.31 Loss of -72 on sale
2025-02-13BUY9959.19059.540 59.505USD 5,891 58.26
2025-02-12BUY3359.68060.020 59.986USD 1,980 58.23
2025-02-11BUY13259.85060.680 60.597USD 7,999 58.19
2024-12-30SELL-1,21054.21054.450 54.426USD -65,855 57.96 Profit of 4,271 on sale
2024-11-18SELL-54055.25057.200 57.005USD -30,783 58.72 Profit of 924 on sale
2024-11-08SELL-3661.44062.270 62.187USD -2,239 58.36 Loss of -138 on sale
2024-10-21SELL-3659.28060.350 60.243USD -2,169 0.00 Loss of -2,169 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ANIP

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1941,035062,69465.5%
2025-09-1872,43315,812127,36656.9%
2025-09-17122,1913,115207,45658.9%
2025-09-1635,7570163,99721.8%
2025-09-1578,19212144,94053.9%
2025-09-1230,941065,76247.0%
2025-09-1139,4190128,05430.8%
2025-09-1072,16858132,79754.3%
2025-09-09142,073160263,39553.9%
2025-09-0835,4900162,39021.9%
2025-09-0551,45850145,84635.3%
2025-09-0465,824100152,24143.2%
2025-09-0362,1760181,21034.3%
2025-09-0244,4730124,88935.6%
2025-08-2940,67425093,99243.3%
2025-08-2899,1680164,69860.2%
2025-08-2729,32710090,65032.4%
2025-08-2665,7770199,75832.9%
2025-08-2537,903364120,27531.5%
2025-08-2258,26265139,88541.6%
2025-08-2169,041150233,24029.6%
2025-08-2040,2980144,83227.8%
2025-08-19128,5790350,79136.7%
2025-08-1872,497100270,47826.8%
2025-08-1563,2900374,91316.9%
2025-08-1491,4458,700225,23240.6%
2025-08-13105,5354,110254,50141.5%
2025-08-12176,94729,770533,07033.2%
2025-08-11231,2655,230706,29832.7%
2025-08-08294,25516,527803,62336.6%
2025-08-07220,706185397,61655.5%
2025-08-06294,1680430,47468.3%
2025-08-0548,125071,57567.2%
2025-08-0435,419053,13966.7%
2025-08-0159,471092,37464.4%
2025-07-3147,901084,85256.5%
2025-07-3045,147095,24847.4%
2025-07-29109,8130199,72655.0%
2025-07-2874,1490114,22664.9%
2025-07-25101,3830158,63863.9%
2025-07-2480,0320117,73168.0%
2025-07-2388,6610122,05972.6%
2025-07-2257,1201,84570,26481.3%
2025-07-2159,2640141,59341.9%
2025-07-1873,816200109,09167.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.